The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia

W. H. Chow, W. D. Finkle, J. K. McLaughlin, H. Frankl, H. K. Ziel and J. F. Fraumeni Jr
Division of Cancer Etiology, National Cancer Institute, Bethesda, Md, USA.

OBJECTIVE--To examine the relationship of gastrointestinal disorders and their treatment to the risk of adenocarcinomas of the esophagus and gastric cardia (AEC). DESIGN--A medical record-based case-control study, with data collected on a standardized form by a trained abstractor, blind to the case-control status. SETTING--A large prepaid health plan. SUBJECTS--Case patients were plan members newly diagnosed with histologically confirmed AEC from 1986 to 1992. For each of the 196 eligible case patients, one control was selected who matched for membership at time of diagnosis, sex, year of birth, and duration of membership. MAIN OUTCOME MEASURES--Association between AEC and history of gastroesophageal conditions and their treatment. Conditional logistic regression procedures were used for calculation of odds ratios (ORs) and corresponding 95% confidence intervals (Cls), with adjustment for race, smoking status, and body mass index. Medications were grouped into H2 antagonists (cimetidine, ranitidine, famotidine, and nizatidine) and anticholinergics (propantheline bromide, dicyclomine hydrochloride, Donnatal [combination of atropine sulfate, hyoscyamine sulfate, phenobarbital, and scopolamine hydrobromide], and Librax [combination of chlordiazepoxide hydrochloride and clidinium bromide]). RESULTS--Significant twofold or greater risks of AEC were associated with a history of esophageal reflux, hiatal hernia, esophagitis/esophageal ulcer, and difficulty swallowing. The ORs increased with increasing number of these conditions. Although a fourfold risk was linked to four or more prescriptions for H2 antagonists, the risk was reduced to 1.5 (95% Cl, 0.4 to 5.4) after adjusting for the predisposing conditions. Further analysis revealed that the excess risk was restricted to persons with a history of gastroesophageal reflux and related conditions. No association was observed for overall use of anticholinergics. However, after adjustment for predisposing conditions, ORs decreased with increasing number of prescriptions for anticholinergics (P for trend = .08) CONCLUSIONS--This study provides reassuring findings that use of H2 antagonists and anticholinergics does not increase AEC risk. It also quantifies the elevated risk of AEC associated with gastroesophageal reflux disease. Further research into reflux disease and the production of premalignant epithelial changes may help elucidate carcinogenic mechanisms and measures aimed at early detection and prevention of AEC.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Chemoprevention of esophageal adenocarcinoma
Abrams
Therapeutic Advances in Gastroenterology 2008;1:7-18.
ABSTRACT  

Leptin and the risk of Barrett's oesophagus
Kendall et al.
Gut 2008;57:448-454.
ABSTRACT | FULL TEXT  

Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus
Whiteman et al.
Gut 2008;57:173-180.
ABSTRACT | FULL TEXT  

Acid inhibitory medication and risk of gastric and oesophageal cancer.
McColl
Gut 2006;55:1532-1533.
FULL TEXT  

Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK
Rodriguez et al.
Gut 2006;55:1538-1544.
ABSTRACT | FULL TEXT  

Mutagen Sensitivity and Neoplastic Progression in Patients with Barrett's Esophagus: A Prospective Analysis.
Chao et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:1935-1940.
ABSTRACT | FULL TEXT  

The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden
Ye et al.
Carcinogenesis 2006;27:1835-1841.
ABSTRACT | FULL TEXT  

Carbonated soft drinks and risk of esophageal adenocarcinoma: a population-based case-control study.
Lagergren et al.
JNCI J Natl Cancer Inst 2006;98:1158-1161.
ABSTRACT | FULL TEXT  

Airborne occupational exposures and risk of oesophageal and cardia adenocarcinoma
Jansson et al.
Occup. Environ. Med. 2006;63:107-112.
ABSTRACT | FULL TEXT  

Carbonated Soft Drink Consumption and Risk of Esophageal Adenocarcinoma
Mayne et al.
JNCI J Natl Cancer Inst 2006;98:72-75.
ABSTRACT | FULL TEXT  

Epidemiology and costs of chronic obstructive pulmonary disease
Chapman et al.
Eur Respir J 2006;27:188-207.
FULL TEXT  

Adenocarcinoma of the Esophagus and Cardia: A Review of the Disease and Its Treatment
DeMeester
Ann. Surg. Oncol. 2006;13:12-30.
ABSTRACT | FULL TEXT  

Interactions among Smoking, Obesity, and Symptoms of Acid Reflux in Barrett's Esophagus
Smith et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:2481-2486.
ABSTRACT | FULL TEXT  

Socioeconomic Factors and Risk of Esophageal Adenocarcinoma: A Nationwide Swedish Case-Control Study
Jansson et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1754-1761.
ABSTRACT | FULL TEXT  

No Association between Gastroesophageal Reflux and Cancers of the Larynx and Pharynx
Nilsson et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1194-1197.
ABSTRACT | FULL TEXT  

Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?
Lagergren
Gut 2005;54:i1-i5.
ABSTRACT | FULL TEXT  

Oesophageal cancer and gastro-oesophageal reflux: what is the relationship?
Lagergren
Gut 2004;53:1064-1065.
FULL TEXT  

Gastroesophageal Reflux Disease, Barrett Esophagus, and Esophageal Adenocarcinoma
Chang and Katzka
Arch Intern Med 2004;164:1482-1488.
ABSTRACT | FULL TEXT  

Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs
Dent et al.
Gut 2004;53:iv1-iv24.
ABSTRACT | FULL TEXT  

Multiple Management Modalities in Esophageal Cancer: Epidemiology, Presentation and Progression, Work-up, and Surgical Approaches
Koshy et al.
The Oncologist 2004;9:137-146.
ABSTRACT | FULL TEXT  

Studies of acid exposure immediately above the gastro-oesophageal squamocolumnar junction: evidence of short segment reflux
Fletcher et al.
Gut 2004;53:168-173.
ABSTRACT | FULL TEXT  

Population Attributable Risks of Esophageal and Gastric Cancers
Engel et al.
JNCI J Natl Cancer Inst 2003;95:1404-1413.
ABSTRACT | FULL TEXT  

Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project
Murray et al.
Int J Epidemiol 2003;32:645-650.
ABSTRACT | FULL TEXT  

Obesity and Estrogen as Risk Factors for Gastroesophageal Reflux Symptoms
Nilsson et al.
JAMA 2003;290:66-72.
ABSTRACT | FULL TEXT  

Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia
Ye and Nyren
Gut 2003;52:938-941.
ABSTRACT | FULL TEXT  

Diet, Obesity and Reflux in the Etiology of Adenocarcinomas of the Esophagus and Gastric Cardia in Humans
Mayne and Navarro
J. Nutr. 2002;132:3467S-3470.
ABSTRACT | FULL TEXT  

Gastroesophageal Reflux, Barrett Esophagus, and Esophageal Cancer: Scientific Review
Shaheen and Ransohoff
JAMA 2002;287:1972-1981.
ABSTRACT | FULL TEXT  

Gastroesophageal Reflux, Barrett Esophagus, and Esophageal Cancer: Clinical Applications
Shaheen and Ransohoff
JAMA 2002;287:1982-1986.
ABSTRACT | FULL TEXT  

Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA
El-Serag et al.
Gut 2002;50:368-372.
ABSTRACT | FULL TEXT  

Site distribution of oesophagogastric cancer
Byrne et al.
J. Clin. Pathol. 2002;55:191-194.
ABSTRACT | FULL TEXT  

Nutrient Intake and Risk of Subtypes of Esophageal and Gastric Cancer
Mayne et al.
Cancer Epidemiol. Biomarkers Prev. 2001;10:1055-1062.
ABSTRACT | FULL TEXT  

Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends
Howe et al.
JNCI J Natl Cancer Inst 2001;93:824-842.
ABSTRACT | FULL TEXT  

Long-term Outcome of Medical and Surgical Therapies for Gastroesophageal Reflux Disease: Follow-up of a Randomized Controlled Trial
Spechler et al.
JAMA 2001;285:2331-2338.
ABSTRACT | FULL TEXT  

Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota
Conio et al.
Gut 2001;48:304-309.
ABSTRACT | FULL TEXT  

Correlation of oesophageal acid exposure with Barrett's oesophagus length
Fass et al.
Gut 2001;48:310-313.
ABSTRACT | FULL TEXT  

The Burning Issue of Chronic Gastroesophageal Reflux
Eisen
ANN INTERN MED 2000;133:227-229.
FULL TEXT  

Symptomatic gastro-oesophageal reflux as a risk factor for oesophageal adenocarcinoma
CAMERON and ROMERO
Gut 2000;46:754-755.
FULL TEXT  

Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study
Peters et al.
Gut 1999;45:489-494.
ABSTRACT | FULL TEXT  

Gastroesophageal Reflux and Adenocarcinoma of the Esophagus
Nandurkar et al.
NEJM 1999;341:536-538.
FULL TEXT  

The Rising Incidence of Gastric Cardia Cancer
Devesa and Fraumeni
JNCI J Natl Cancer Inst 1999;91:747-749.
FULL TEXT  

Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma
Lagergren et al.
NEJM 1999;340:825-831.
ABSTRACT | FULL TEXT  

Comparative Genomic Hybridization of Cancer of the Gastroesophageal Junction: Deletion of 14Q31-32.1 Discriminates between Esophageal (Barrett's) and Gastric Cardia Adenocarcinomas
van Dekken et al.
Cancer Res. 1999;59:748-752.
ABSTRACT | FULL TEXT  

Adenocarcinoma of the Esophagus and Gastric Cardia: Is There Progress in the Face of Increasing Cancer Incidence?
Sampliner
ANN INTERN MED 1999;130:67-69.
FULL TEXT  

Evidence based case reports
Perry et al.
BMJ 1998;317:1386b-1386.
FULL TEXT  

Gastro-oesophageal reflux in infants under 6 months with cystic fibrosis
Heine et al.
Arch. Dis. Child. 1998;78:44-48.
ABSTRACT | FULL TEXT  

Ten years' experience of screening patients with Barrett's oesophagus in a university teaching hospital
Macdonald et al.
Gut 1997;41:303-307.
ABSTRACT | FULL TEXT  

Long-Term Therapy for Reflux Esophagitis
Tytgat
NEJM 1995;333:1148-1150.
FULL TEXT